In the context of exendin-4, the -phe1 substitution is known to reduce binding affinity, reduce GLP-1R endocytosis, accelerate GLP-1R recycling, enhance insulin release, and improve anti-hyperglycaemic efficacy, while exendin-asp3 shows opposing characteristics (Jones et al., 2018b)
Apart from energy metabolism, it also possesses cognitive benefits
This allows central arousal signaling without broad endocrine disruption
Initial improvements in hydration may appear within two weeks
Most people notice some degree of reduced appetite within the first one to three weeks, with 86% of clinical trial participants reporting eating behavior changes within the first eight weeks
Providers conduct individualized risk-benefit analysis, examining personal and family history of medullary thyroid cancer (MTC), multiple endocrine neoplasia type 2 (MEN2), pancreatitis, and severe diabetic retinopathy